Gehin C et al. CERT1 mutations perturb human development by disrupting sphingolipid homeostasis. J Clin Invest. 2023 May 15;133(10):e165019.
doi: 10.1172/JCI165019. PMID: 36976648.
de Ligt J et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367:1921-1929. PMID: 23033978.
Fitzgerald TW et al. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519:223-228. PMID: 25533962.
Hamdan FF et al. De novo mutations in moderate or severe intellectual disability. PLoS Genet. 2014;10:e1004772. PMID: 25356899.
Kosmicki JA et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat Genet. 2017;49:504-510. PMID: 28191890.
Lelieveld SH et al. Spatial Clustering of de Novo Missense Mutations Identifies Candidate Neurodevelopmental Disorder-Associated Genes. Am J Hum Genet. 2017;101:478-484. PMID: 28867141.
Murakami H et al. Intellectual disability-associated gain-of-function mutations in CERT1 that encodes the ceramide transport protein CERT. PLoS One. 2020;15(12):e0243980. PMID: 33347465.
Takata A et al. Integrative Analyses of De Novo Mutations Provide Deeper Biological Insights into Autism Spectrum Disorder. Cell Rep. 2018;22:734-747. PMID: 29346770.
Tamura N et al. Intellectual disability-associated mutations in the ceramide transport protein gene CERT1 lead to awberrant function and subcellular distribution. J Biol Chem. 2021;297(5): article 101338. PMID: 34688657.
Wang T et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. Nat Commun. 2016;7:13316. PMID: 27824329.